TREATMENT PREFERENCE ON THE NEW SUBCUTANEOUS IMMUNOGLOBULIN 20% (SCIG 20%) TREATMENT IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) IN EUROPE (EU)
2017
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI